Hyperthyroidism
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Initial work-up for a first low TSH that remains > 0.1 mIU/L
Laboratory tests in 6 weeks
- TSH
- Free T4 as a reflex test if TSH remains lowif neededTSH confirmed low (between 0.1 and 0.4 mIU/L) on repeat: free T4 as a reflex test on the same sample, then free T3 as a reflex test if free T4 is normal [1].
- State on the request: "follow-up TSH, reflex assays".
Do not order
Initial work-up for a TSH < 0.1 mIU/L or a repeatedly low TSH
Laboratory tests
- TSH
- Free T4
- TSH receptor antibodies (TRAb)
- free T3 assay if TSH low and free T4 normalif neededIf TSH low and free T4 normal.
- CRPif neededSuspected De Quervain thyroiditis (raised CRP).
- Thyroglobulin (if factitious thyrotoxicosis suspected)if neededSuspected covert intake of thyroid hormones: a low or undetectable thyroglobulin, in the absence of anti-thyroglobulin antibodies, establishes the diagnosis [1].
- Anti-thyroglobulin antibodies (with thyroglobulin, if factitious thyrotoxicosis suspected)if neededSuspected covert intake of thyroid hormones: anti-thyroglobulin antibodies validate the thyroglobulin measurement [1,2].
Do not order
- Anti-TPO antibodies first-line: no place in the aetiological diagnosis in primary care; second-line, after specialist advice, if TRAb are negative [1].
- Anti-thyroglobulin antibodies: useless for investigating hyperthyroidism, except to validate a thyroglobulin measurement [1,2].
- Free T3 outside T3 hyperthyroidism (low TSH, normal free T4) or outside amiodarone [1].
Tests on antithyroid drugs
Laboratory tests before starting treatment
- FBC
- TSH
- Free T4 (or free T3 in T3 hyperthyroidism)
- ASTWarning sign of hepatitis; the SFE and the GRT also suggest a check before initiation and after 3 or 4 weeks.
- ALTWarning sign of hepatitis; the SFE and the GRT also suggest a check before initiation and after 3 or 4 weeks.
- GGTWarning sign of hepatitis; the SFE and the GRT also suggest a check before initiation and after 3 or 4 weeks.
- Alkaline phosphataseWarning sign of hepatitis; the SFE and the GRT also suggest a check before initiation and after 3 or 4 weeks.
FBC every week for the first 6 weeks
- FBC (one a week, 6 in total)
- If fever, sore throat or sign of infection: stop the antithyroid drug and do an urgent FBC.
Laboratory tests between day 21 and day 42
- Free T4 (or free T3 in T3 hyperthyroidism)
- Free T3 (in addition to free T4)if needednon-French guidelineAmerican and British practice: the American Thyroid Association measures free T4 and T3 from 2 to 6 weeks of treatment, as free T4 may normalise while T3 remains high [4]; NICE measures TSH, free T4 and free T3 every 6 weeks until TSH normalises [3]. HAS asks for free T3 only if it was initially abnormal [1].
- ASTif neededWarning sign of liver damage (jaundice, pale stools, dark urine, abdominal pain, pruritus): liver function tests without delay [1,8]. No consensus for routine monitoring [1,9]; stop the antithyroid drug if clinical hepatitis or transaminases > 3 times normal [9].
- ALTif neededWarning sign of liver damage (jaundice, pale stools, dark urine, abdominal pain, pruritus): liver function tests without delay [1,8]. No consensus for routine monitoring [1,9]; stop the antithyroid drug if clinical hepatitis or transaminases > 3 times normal [9].
- GGTif neededWarning sign of liver damage (jaundice, pale stools, dark urine, abdominal pain, pruritus): liver function tests without delay [1,8]. No consensus for routine monitoring [1,9]; stop the antithyroid drug if clinical hepatitis or transaminases > 3 times normal [9].
- Alkaline phosphataseif neededWarning sign of liver damage (jaundice, pale stools, dark urine, abdominal pain, pruritus): liver function tests without delay [1,8]. No consensus for routine monitoring [1,9]; stop the antithyroid drug if clinical hepatitis or transaminases > 3 times normal [9].
Laboratory tests at day 60 (M2)
- Free T4 (or free T3 in T3 hyperthyroidism)
- Repeat every 3-6 weeks until free T4 normalises
TSH every 2 to 4 months thereafter
- TSH
Do not order
Follow-up tests when stopping antithyroid drugs
Before the decision to stop treatment
- TSH receptor antibodies
After stopping: at 6-8 weeks, 3 months, 6 months and 12 months
- TSH (6 to 8 weeks, 3, 6 and 12 months after stopping, then at least once a year)
- Free T4 as a reflex test if TSH is lowif neededLow TSH at a check: free T4 is measured as a reflex test on the same sample [1,2].
- Free T3 as a reflex test (initial T3 hyperthyroidism)if neededT3 hyperthyroidism: low TSH and normal free T4, free T3 is measured as a reflex test [1].
Do not order
Child: low TSH or suspected hyperthyroidism
Laboratory tests
- TSH
- Free T4
- Free T3
- TSH receptor antibodies (TRAb)
- Anti-thyroid peroxidase (TPO) antibodies
- FBC (neutrophils)if needednon-French guidelineConfirmed hyperthyroidism: baseline tests before an antithyroid drug, as both the disease and the treatment can alter neutrophils and liver function tests [15].
- ASTif needednon-French guidelineConfirmed hyperthyroidism: baseline tests before an antithyroid drug, as both the disease and the treatment can alter neutrophils and liver function tests [15].
- ALTif needednon-French guidelineConfirmed hyperthyroidism: baseline tests before an antithyroid drug, as both the disease and the treatment can alter neutrophils and liver function tests [15].
Sources (15)
- Haute Autorité de santé. Prise en charge des hyperthyroïdies chez l’adulte (population générale). Recommandation de bonne pratique, validée par le Collège le 15 décembre 2022 (texte des recommandations et fiche de synthèse).
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1208 (TSH), 1209 (T3L + T4L), 1212 (TSH + T4L + T3L), 1488 (anticorps antirécepteurs de la TSH).
- National Institute for Health and Care Excellence (NICE). Thyroid disease: assessment and management. NICE guideline NG145, publiée le 20 novembre 2019, mise à jour le 12 octobre 2023 (recommandations 1.2.8 à 1.2.10, 1.6.1 à 1.6.3, 1.6.21, 1.7.9 à 1.7.11, 1.8.1 à 1.8.3, et leur justification).
- Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
- Hennessey JV. Subacute thyroiditis. In: Feingold KR, Adler RA, Ahmed SF, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com; mise à jour du 7 janvier 2026.
- Martinez Quintero B, Yazbeck C, Sweeney LB. Thyroiditis: Evaluation and Treatment. Am Fam Physician. 2021;104(6):609-617.
- Conseil scientifique du domaine de la santé (Luxembourg). Le bilan biologique thyroïdien en médecine générale. Mise à jour 2020, reconduite en 2025.
- Résumé des caractéristiques du produit NEO-MERCAZOLE 5 mg, comprimé (carbimazole), rubriques 4.2 et 4.4 (ANSM, mis à jour le 07/10/2025). Base de données publique des médicaments.
- Corvilain B, Hamy A, Brunaud L, Borson-Chazot F, Orgiazzi J, Bensalem Hachmi L, Semrouni M, Rodien P, Lussey-Lepoutre C. Treatment of adult Graves’ disease (consensus de la Société française d’endocrinologie). Ann Endocrinol (Paris). 2018;79(6):618-635.
- Résumé des caractéristiques du produit BASDENE 25 mg, comprimé (benzylthiouracile), rubriques 4.2 et 4.4 (ANSM, mis à jour le 06/02/2025). Base de données publique des médicaments.
- Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
- Résumé des caractéristiques du produit THYROZOL 10 mg, comprimé pelliculé sécable (thiamazole), rubrique 4.4 (ANSM, mis à jour le 11/04/2023). Base de données publique des médicaments.
- Centre belge d’information pharmacothérapeutique (CBIP). Répertoire commenté des médicaments, édition 2021, chapitre 5.2.3 « Antithyroïdiens ».
- Spaulding SW. Are biweekly granulocyte counts effective in forecasting the onset of agranulocytosis in patients with Graves’ disease who are receiving antithyroid drugs? Clin Thyroidol. 2013;25(11):244-246 (commentaire de Nakamura H et al., J Clin Endocrinol Metab 2013, doi:10.1210/jc.2013-2569).
- Mooij CF, Cheetham TD, Verburg FA, Eckstein A, Pearce SH, Léger J, van Trotsenburg ASP. 2022 European Thyroid Association guideline for the management of pediatric Graves' disease. Eur Thyroid J 2022;11(1):e210073.